RxDoctor Payments Data

Kevin Traynor, MD

Cardiology · Port Saint Lucie, FLNPI 1578538690

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abbott at 46.5% of the total. Reporting peaked in 2019 at $433 and has fallen 88.9% since, to $48 in 2023. That places this record below the midpoint for cardiology clinicians in FL, where the typical reported total is $307.

$939in general payments, 2019–2025

Across 30 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$437
  • Johnson & Johnson$196
  • Novartis$135
  • Boehringer Ingelheim$53
  • AstraZeneca$39
  • Teva Pharmaceuticals USA, Inc.$31
  • plus $48 from 2 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 50th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$313,834
Medicare patients
284
Services billed
2,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban23$25,150
Amiodarone Hcl16$1,367
Flecainide Acetate36$1,351
Amlodipine Besylate63$656
Diclofenac Sodium12$565
Losartan Potassium51$522
Atorvastatin Calcium28$445
Metoprolol Tartrate58$430
Metoprolol Succinate16$348
Digoxin12$266
Potassium Chloride14$244
Furosemide36$244
ClopidogrelClopidogrel Bisulfate12$238
Pantoprazole Sodium15$232
Tamsulosin Hcl13$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$196$25,15023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 45 cardiology providers in Florida.

Other cardiology in Port Saint Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →